<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21577" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Factor V Leiden Mutation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Albagoush</surname>
            <given-names>Sara A.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koya</surname>
            <given-names>Supriya</given-names>
          </name>
          <aff>Genesis Care</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chakraborty</surname>
            <given-names>Rebanta K.</given-names>
          </name>
          <aff>Steward Medical\Good Samaritan Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schmidt</surname>
            <given-names>Amy E.</given-names>
          </name>
          <aff>University of Rochester</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sara Albagoush declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Supriya Koya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rebanta Chakraborty declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amy Schmidt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21577.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Factor V Leiden (FVL) is a point mutation of factor V resulting in an elimination of the cleavage site in factor V and factor Va. This genetic defect increases the risk of thrombosis, especially in homozygous or pseudo-homozygous FVL-mutated individuals. Many individuals with the mutation will never develop a venous thrombotic event (VTE). The decision about VTE risk reduction (both primary and secondary) requires a great deal of clinical acumen, given that most people who carry the mutation will never have VTE. FVL is an autosomal dominant genetic condition that exhibits incomplete penetrance, meaning that not every person with the mutation will develop the disease. This activity reviews the pathophysiology and implications of factor V Leiden and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of FVL.</p></list-item><list-item><p>Review the clinical manifestations of FVL, including the importance of combined thrombophilia conditions.</p></list-item><list-item><p>Review the prophylaxis for venous thromboembolism during pregnancy and during the postpartum period for women with FVL with or without a family history of thromboembolism.</p></list-item><list-item><p>Summarize the treatment options for FVL.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21577&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21577">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21577.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Factor V Leiden is a point mutation of factor V, resulting in an elimination of the cleavage site in factor V and factor Va. This genetic defect&#x000a0;leads to an increased risk of thrombosis, especially in homozygous or pseudo-homozygous factor V Leiden mutations.&#x000a0;Many individuals with the mutation will never develop a venous thrombotic event (VTE). The decision about VTE risk reduction (both primary and secondary and prevention of recurrence) requires a great deal of clinical acumen, given that most people who carry the mutation will never have VTE.</p>
      </sec>
      <sec id="article-21577.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Normally, factor V synthesis principally occurs in the liver. Thrombin activates factor V, and once activated, it will convert prothrombin to thrombin. Activated protein C, one of the principal physiologic inhibitors of coagulation, degrades factor V. In the presence of what is called thrombomodulin, thrombin acts to decrease clotting by activating protein C; therefore, the concentration and the action of protein C are important determinants in the negative feedback loop through which thrombin limits its activation.</p>
        <p>Factor V Leiden is an autosomal dominant genetic condition that exhibits incomplete penetrance, meaning that not every person with the mutation will develop&#x000a0;the disease.&#x000a0;</p>
        <p>Factor V Leiden, also known as factor VR506Q and factor V Arg506 Gln, results from a single-point mutation in the factor V gene (guanine to adenine at nucleotide 1691), which leads to a single amino acid change (replacement of arginine with glutamine at amino acid 506). This abolishes the Arg506 cleavage site for activated protein C in Factor V and Va.<xref ref-type="bibr" rid="article-21577.r1">[1]</xref>&#x000a0;Factor&#x000a0;V Leiden increases the risk of thrombosis as activated protein C, a natural anticoagulant, can not bind and inactivate factor V as there is a mutation in the binding site on factor V for activated protein C. Therefore, as factor V is not inactivated, it continues to be active and increases thrombosis risk.</p>
      </sec>
      <sec id="article-21577.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Heterozygosity of the factor V Leiden mutation is the most common inherited thrombophilia in the unselected White population&#x000a0;(prevalence, approximately 1% to 5%) and is considered the most common inherited thrombophilia in individuals with venous thromboembolism&#x000a0;(prevalence of roughly 10% to 20%).<xref ref-type="bibr" rid="article-21577.r2">[2]</xref>&#x000a0;Heterozygosity of this genetic mutation increases the lifetime risk of thrombosis by about 7-fold, while homozygosity (which is rare) increases the risk by approximately 20-fold. Despite the increase in the risk of VTE, there is no clinical evidence that heterozygosity of factor V Leiden increases overall mortality.</p>
      </sec>
      <sec id="article-21577.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Factor V Leiden results from a single-point mutation in the factor V gene (guanine to adenine at nucleotide 1691) that would lead to the replacement of arginine with glutamine at amino acid 506.&#x000a0;This abolishes the Arg506 cleavage site for activated protein C in factor V and factor Va. The consequences are enhancing the procoagulant role of factor Va and the reduced anticoagulant role of factor V.<xref ref-type="bibr" rid="article-21577.r1">[1]</xref></p>
      </sec>
      <sec id="article-21577.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The primary clinical manifestation of the factor V Leiden mutation is the risk for venous thromboembolism&#x000a0;(VTE). However, the most common finding in individuals with factor V Leiden is a laboratory-only abnormality. Only a small percentage of individuals with factor V Leiden will develop VTE in their lifetime, with an approximate risk of 5% for factor V Leiden heterozygotes in the general population and up to 20% in thrombophilic families.</p>
        <p>
<bold>Venous Thromboembolism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The most common site of VTE is deep vein thrombosis (DVT) and pulmonary embolism (PE), but other sites, including superficial veins of the legs or cerebral, portal, and hepatic veins, may be involved.<xref ref-type="bibr" rid="article-21577.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Isolated PE is a less common presentation. Without evidence of DVT, factor V Leiden patients can still present with PE. But this is a less common presentation of VTE in individuals with factor V Leiden compared with the general population, a phenomenon called the factor V Leiden paradox.<xref ref-type="bibr" rid="article-21577.r4">[4]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cerebral vein thrombosis can occur in factor V Leiden individuals, especially in patients using oral contraceptive pills. Studies have shown that factor V Leiden can be&#x000a0;associated with an increased risk of Budd-Chiari syndrome.<xref ref-type="bibr" rid="article-21577.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Arterial Thromboembolism</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The association between factor V Leiden and arterial thromboembolism remains controversial, and it is likely to be small if present.</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction: Studies have shown a modest increase in the risk of coronary artery disease in patients with factor V Leiden. It has been observed that the factor V Leiden mutation is associated with an increased risk of stroke, especially in women, smokers, and younger individuals.<xref ref-type="bibr" rid="article-21577.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pregnancy and Postpartum Thromboembolism Risk</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Thromboembolism affects 1.2 of every 1000 deliveries.<xref ref-type="bibr" rid="article-21577.r7">[7]</xref>&#x000a0;Increased morbidity and mortality are reported with pregnancy-associated VTE&#x000a0;for women&#x000a0;<xref ref-type="bibr" rid="article-21577.r8">[8]</xref><xref ref-type="bibr" rid="article-21577.r9">[9]</xref>. However, based on current clinical evidence, inherited thrombophilias like factor V Leiden are neither considered risk factors for recurrent pregnancy losses nor implicated in affecting obstetrical outcomes.<xref ref-type="bibr" rid="article-21577.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Women with factor V Leiden and other inherited thrombophilia with or without a family history of VTE are at increased risk of VTE and VTE-related complications during pregnancy.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21577.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Testing for thrombophilia conditions in patients diagnosed with the first episode of DVT/PE is being discouraged according to the American Society of Hematology (ASH) guidelines as it is expensive with no clinically meaningful benefit.</p>
        <p>Testing for factor V Leiden is indicated&#x000a0;for individuals with venous thromboembolism, especially if:</p>
        <list list-type="bullet">
          <list-item>
            <p>VTE occurs at a young age, generally speaking, less than 50 yrs of age</p>
          </list-item>
          <list-item>
            <p>Atypical sites of clotting like visceral vein thromboses like an ovarian vein, portal vein, or renal vein thrombosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unexplained arterial thrombosis</p>
          </list-item>
          <list-item>
            <p>Significant family history of thrombophilia</p>
          </list-item>
          <list-item>
            <p>In a hospitalized patient developing VTE despite being on prophylactic anticoagulation with no other definite explanation for VTE&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Unexplained recurrent deep venous thrombosis/PE</p>
          </list-item>
        </list>
        <p>Testing usually is not performed in individuals with a first episode, especially if it is provoked or if it occurs in people who&#x000a0;are older than 50 years of age.</p>
        <p>Factor V Leiden can be diagnosed&#x000a0;by mutation&#x000a0;analysis&#x000a0;(genetic testing) or using a functional coagulation test&#x000a0;for&#x000a0;APC&#x000a0;resistance.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Genetic testing</italic>&#x000a0;is&#x000a0;indicated&#x000a0;for those with a family history of factor V Leiden. It is also preferred for members of a thrombophilic family, patients with antiphospholipid syndrome, or those who need to be on an anticoagulant. Individuals with&#x000a0;a positive&#x000a0;functional assay for&#x000a0;APC&#x000a0;resistance should have genetic testing to confirm a diagnosis.<xref ref-type="bibr" rid="article-21577.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Mutation testing:</italic> Polymerase&#x000a0;chain reaction methods can detect factor V Leiden mutation. The DNA from individuals without the mutation would be 'cut' by a restriction enzyme. In contrast, it will not cut DNA in patients with factor V Leiden mutation resulting in a different banding pattern on a DNA gel.<xref ref-type="bibr" rid="article-21577.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Functional APC&#x000a0;resistance assays:</italic> These tests cost less than genetic testing, but in rare cases, they can give a misleading, falsely normal result, especially in individuals on therapy with direct thrombin inhibitors or factor Xa inhibitors,&#x000a0;as well as in the presence of a lupus anticoagulant.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21577.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of venous thromboembolism in people with factor V Leiden mutation is the same as that of the general population, and factor V Leiden mutation will not affect the decision about which anticoagulant one should use. The choice of anticoagulant is based on some factors like patient preference, adherence to therapy, the severity of thrombosis, and drug interactions.&#x000a0;</p>
        <p>Generally,&#x000a0;direct oral anticoagulants (DOAC) are usually used for patients with typical VTE presentations. Warfarin is preferred if there&#x000a0;is a concern&#x000a0;about adherence or for those who present with a submassive/massive pulmonary embolism who would benefit from&#x000a0;maintaining INR at the high end of the therapeutic range.</p>
        <p>The duration of VTE treatment is not different between factor V Leiden and the general population, and it depends on the risk of recurrent VTE. It is highly recommended&#x000a0;that one continue indefinite anticoagulation for unprovoked, life-threatening venous thromboembolism, VTE at an unusual location or if it is recurrent.<xref ref-type="bibr" rid="article-21577.r13">[13]</xref></p>
        <p>Individuals with factor V Leiden homozygous mutation who undergo surgery should be treated as a high-risk group and receive prophylactic anticoagulation.</p>
      </sec>
      <sec id="article-21577.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for deep vein thrombosis (DVT) includes&#x000a0;the following:</p>
        <p>
<bold>Inherite</bold>
<bold>d Thrombophilia</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prothrombin G20210A mutation</p>
          </list-item>
          <list-item>
            <p>Protein S deficiency&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Protein C deficiency</p>
          </list-item>
          <list-item>
            <p>Antithrombin (AT) deficiency</p>
          </list-item>
        </list>
        <p>
<bold>Others</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Malignancy</p>
          </list-item>
          <list-item>
            <p>Trauma/surgery</p>
          </list-item>
          <list-item>
            <p>Pregnancy or use of oral contraceptives</p>
          </list-item>
          <list-item>
            <p>Immobilization/obesity</p>
          </list-item>
          <list-item>
            <p>Nephrotic syndrome</p>
          </list-item>
          <list-item>
            <p>Antiphospholipid syndrome&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Paroxysmal nocturnal hemoglobinuria</p>
          </list-item>
          <list-item>
            <p>Myeloproliferative disorders</p>
          </list-item>
          <list-item>
            <p>Heart failure&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Severe liver disease.cirrhosis</p>
          </list-item>
          <list-item>
            <p>Medications like tamoxifen, thalidomide, or lenalidomide</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21577.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>A proportion of the population with factor V Leiden will suffer from venous thrombosis. Thromboembolism, including pulmonary embolism, carries significant morbidity and mortality.&#x000a0;However, despite the increase in the risk of VTE, there is no evidence that heterozygosity to factor V Leiden increases overall mortality.</p>
      </sec>
      <sec id="article-21577.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient counseling and education include emphasizing specific aspects of&#x000a0;a healthy lifestyle to improve prognosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>Maintain&#x000a0;a healthy weight, and lose&#x000a0;weight if necessary.</p>
          </list-item>
          <list-item>
            <p>Eat a healthy diet.</p>
          </list-item>
          <list-item>
            <p>Get at least&#x000a0;2.5 hours of exercise per week. Walking is a good choice, but other activities, such as swimming, cycling, running, or playing tennis or team sports, are also good choices.</p>
          </list-item>
          <list-item>
            <p>Do not smoke&#x000a0;since it increases the risk of blood clots. Clinicians&#x000a0;can assist with&#x000a0;stop-smoking programs and medicines&#x000a0;to improve the patient's chances of quitting&#x000a0;permanently.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21577.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Pertinent to factor V Leiden, it&#x000a0;is essential to understand the relative risk of VTE risk compared to other thrombophilia conditions that help to guide management decisions. This risk is&#x000a0;depicted in the below format for easy understanding.</p>
        <table-wrap id="article-21577.table0" position="float" orientation="portrait">
          <table border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>Thrombophilia Condition</bold>
</td>
                <td style="height: 13px;" rowspan="1" colspan="1">
<bold>A relative Increase in the Risk of Thrombosis</bold>
</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Factor V Leiden heterozygous</td>
                <td style="height: 13px;" rowspan="1" colspan="1">4.9 fold (3-8 fold)&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Factor V Leiden homozygous</td>
                <td style="height: 13px;" rowspan="1" colspan="1">16 fold</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Factor V Leiden with other thrombophilia conditions like a prothrombin gene mutation</td>
                <td style="height: 13px;" rowspan="1" colspan="1">20 fold</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Protein C deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">7 fold</td>
              </tr>
              <tr style="height: 35px;">
                <td style="height: 35px;" rowspan="1" colspan="1">
<p>Protein S deficiency</p>
</td>
                <td style="height: 35px;" rowspan="1" colspan="1">7 fold&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Antithrombin III deficiency</td>
                <td style="height: 13px;" rowspan="1" colspan="1">16 fold (up to 20 fold)</td>
              </tr>
              <tr style="height: 13px;">
                <td style="height: 13px;" rowspan="1" colspan="1">Prothrombin gene mutation, heterozygous</td>
                <td style="height: 13px;" rowspan="1" colspan="1">3.8 fold</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>So a patient having conditions like heterozygous factor V Leiden mutation, heterozygous prothrombin gene mutation, protein C, and protein S deficiency do not require lifetime anticoagulation. Thus&#x000a0;patients with these thrombophilia conditions, management is no different than the management guidelines of the general population. Per ASH guidelines, 3&#x000a0;to 6 months of anticoagulation is recommended for the first episode of venous thrombosis. Duration of anticoagulation in individuals with underlying other thrombosis-provoking conditions like malignancy that increases their risk for recurrent DVT needs to be&#x000a0;made based on the underlying condition rather than based on these these thrombophilia conditions.&#x000a0;</p>
      </sec>
      <sec id="article-21577.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Factor V Leiden is not a common disorder, but because there is a potential risk of developing VTE, healthcare&#x000a0;professionals should be aware of this disorder.&#x000a0;Patients may present with either venous or arterial thrombotic events, both of which are associated with high morbidity and mortality. The condition is best managed by an interprofessional team that includes a hematologist, internist, pharmacist, obstetrician, nurses, and primary care provider. The key reason for such a team is that even when a diagnosis is made, many patients with only a laboratory finding of the defect may not require therapy. Only patients with VTE require treatment. Therefore, all interprofessional team members need to familiarize themselves with the condition and be able to offer patient counsel and watch for signs of VTE. This will require interprofessional care coordination and open communication between team members.</p>
        <p>The other difficulty in managing these patients is the duration of therapy. At the moment, data indicate that VTE in factor V Leiden should be managed&#x000a0;in the same manner&#x000a0;as the normal population, but those with recurrent VTE or thrombosis of vessels in unusual locations may require long-term therapy. The outcomes in most patients with factor V Leiden are good, but the outcomes in pregnant&#x000a0;women with the disorder are&#x000a0;serious because of morbidity associated with VTE development and VTE-associated complications in pregnancy.<xref ref-type="bibr" rid="article-21577.r14">[14]</xref><xref ref-type="bibr" rid="article-21577.r15">[15]</xref>&#x000a0;</p>
        <p>To decrease the morbidity and mortality associated with VTE and post-thrombotic syndrome and complications in pregnant women with VTE, anticoagulation recommendations are put forward by the American Society of Hematology (ASH) and the American College of obstetricians and gynecologists (ACOG).<xref ref-type="bibr" rid="article-21577.r16">[16]</xref>&#x000a0;</p>
        <p>Pregnancy being a prothrombotic condition, specific guidelines in managing thrombosis in pregnancy and inherited thrombophilias like factor V Leiden and compound thrombophilias put forward by ASH are summarised in the following table.<xref ref-type="bibr" rid="article-21577.r16">[16]</xref>&#x000a0;</p>
        <table-wrap id="article-21577.table1" position="float" orientation="portrait">
          <table style="width: 1020px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 26px;">
                <td style="width: 110.5px; height: 26px;" rowspan="1" colspan="1">
<bold>Current or past history of thrombosis</bold>
</td>
                <td style="width: 114.125px; height: 26px;" rowspan="1" colspan="1">
<bold>Type of thrombophilia&#x000a0;</bold>
</td>
                <td style="width: 107.734px; height: 26px;" rowspan="1" colspan="1">
<bold>Family history of&#x000a0;VTE&#x000a0;</bold>
</td>
                <td style="width: 175.312px; height: 26px;" rowspan="1" colspan="1">
<bold>Anticoagulation during pregnancy</bold>
</td>
                <td style="width: 116.422px; height: 26px;" rowspan="1" colspan="1">
<p><bold>Anticoagulation postpartum</bold></p>
</td>
                <td style="width: 134.906px; height: 26px;" rowspan="1" colspan="1">
<p><bold>Choice of anticoagulant</bold></p>
<p><bold>*Do not use DOACs during pregnancy&#x000a0;</bold></p>
<p><bold>*Warfarin is not recommended during pregnancy due to teratogenicity</bold></p>
</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 110.5px; height: 26px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 26px;" rowspan="1" colspan="1">Homozygous factor V Leiden</td>
                <td style="width: 107.734px; height: 26px;" rowspan="1" colspan="1">Irrespective of family history</td>
                <td style="width: 175.312px; height: 26px;" rowspan="1" colspan="1">Prophylactic&#x000a0;LMWH throughout pregnancy. Monitoring of anti-Xa levels is not&#x000a0;required.</td>
                <td style="width: 116.422px; height: 26px;" rowspan="1" colspan="1">
<p>Anticoagulation with LMWH is recommended postpartum.</p>
<p>If not breastfeeding, then DOACs can be used.</p>
</td>
                <td style="width: 134.906px; height: 26px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum, especially in breastfeeding women</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 110.5px; height: 26px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 26px;" rowspan="1" colspan="1">Homozygous FVL+ prothrombin gene mutation</td>
                <td style="width: 107.734px; height: 26px;" rowspan="1" colspan="1">Irrespective of family history&#x000a0;</td>
                <td style="width: 175.312px; height: 26px;" rowspan="1" colspan="1">Prophylactic&#x000a0;LMWH throughout pregnancy.</td>
                <td style="width: 116.422px; height: 26px;" rowspan="1" colspan="1">
<p>LMWH in the postpartum period is recommended.</p>
<p>If not breastfeeding, then DOACs can be used</p>
</td>
                <td style="width: 134.906px; height: 26px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum, especially in breastfeeding women.&#x000a0;&#x000a0;</td>
              </tr>
              <tr style="height: 80px;">
                <td style="width: 110.5px; height: 80px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 80px;" rowspan="1" colspan="1">Heterozygous FVL or heterozygous prothrombin gene mutation&#x000a0;</td>
                <td style="width: 107.734px; height: 80px;" rowspan="1" colspan="1">Irrespective of family history&#x000a0;</td>
                <td style="width: 175.312px; height: 80px;" rowspan="1" colspan="1">No need for prophylactic anticoagulation during pregnancy.</td>
                <td style="width: 116.422px; height: 80px;" rowspan="1" colspan="1">No need for prophylactic anticoagulation.</td>
                <td style="width: 134.906px; height: 80px;" rowspan="1" colspan="1">&#x000a0;Not needed</td>
              </tr>
              <tr style="height: 80px;">
                <td style="width: 110.5px; height: 80px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 80px;" rowspan="1" colspan="1">Protein C or S deficiency</td>
                <td style="width: 107.734px; height: 80px;" rowspan="1" colspan="1">Yes</td>
                <td style="width: 175.312px; height: 80px;" rowspan="1" colspan="1">No need for prophylactic anticoagulation.</td>
                <td style="width: 116.422px; height: 80px;" rowspan="1" colspan="1">Postpartum anticoagulation prophylaxis is needed.</td>
                <td style="width: 134.906px; height: 80px;" rowspan="1" colspan="1">LMWH postpartum, especially breastfeeding women.&#x000a0;</td>
              </tr>
              <tr style="height: 80px;">
                <td style="width: 110.5px; height: 80px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 80px;" rowspan="1" colspan="1">Antithrombin III deficiency or homozygous prothrombin gene mutation</td>
                <td style="width: 107.734px; height: 80px;" rowspan="1" colspan="1">Yes</td>
                <td style="width: 175.312px; height: 80px;" rowspan="1" colspan="1">Prophylactic anticoagulation is needed during pregnancy.&#x000a0;</td>
                <td style="width: 116.422px; height: 80px;" rowspan="1" colspan="1">
<p>Postpartum anticoagulation prophylaxis is needed.</p>
<p>If not breastfeeding, then DOACs can be used</p>
</td>
                <td style="width: 134.906px; height: 80px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum,&#x000a0; especially in breastfeeding women&#x000a0;</td>
              </tr>
              <tr style="height: 80.6667px;">
                <td style="width: 110.5px; height: 80.6667px;" rowspan="1" colspan="1">No</td>
                <td style="width: 114.125px; height: 80.6667px;" rowspan="1" colspan="1">Antithrombin III deficiency or homozygous prothrombin gene mutation&#x000a0;</td>
                <td style="width: 107.734px; height: 80.6667px;" rowspan="1" colspan="1">No</td>
                <td style="width: 175.312px; height: 80.6667px;" rowspan="1" colspan="1">
<p>No prophylaxis needed</p>
</td>
                <td style="width: 116.422px; height: 80.6667px;" rowspan="1" colspan="1">&#x000a0;Yes, prophylactic anticoagulation is recommended.</td>
                <td style="width: 134.906px; height: 80.6667px;" rowspan="1" colspan="1">&#x000a0;LMWH during&#x000a0; postpartum&#x000a0;</td>
              </tr>
              <tr style="height: 73px;">
                <td style="width: 110.5px; height: 73px;" rowspan="1" colspan="1">Acute DVT /PE in pregnancy&#x000a0;</td>
                <td style="width: 114.125px; height: 73px;" rowspan="1" colspan="1">Irrespective of the thrombophilia&#x000a0;</td>
                <td style="width: 107.734px; height: 73px;" rowspan="1" colspan="1">Irrespective of family history</td>
                <td style="width: 175.312px; height: 73px;" rowspan="1" colspan="1">
<p>LMW heparin throughout pregnancy and six weeks postpartum</p>
<p>Recommend against thrombolysis&#x000a0;&#x000a0;</p>
</td>
                <td style="width: 116.422px; height: 73px;" rowspan="1" colspan="1">
<p>LMWH</p>
<p>Routine anti-Xa monitoring is not necessary&#x000a0;</p>
</td>
                <td style="width: 134.906px; height: 73px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum,&#x000a0; especially in breastfeeding women&#x000a0;</td>
              </tr>
              <tr style="height: 13px;">
                <td style="width: 110.5px; height: 13px;" rowspan="1" colspan="1">Superficial venous thrombosis</td>
                <td style="width: 114.125px; height: 13px;" rowspan="1" colspan="1">Irrespective of thrombophilia</td>
                <td style="width: 107.734px; height: 13px;" rowspan="1" colspan="1">Irrespective of family history</td>
                <td style="width: 175.312px; height: 13px;" rowspan="1" colspan="1">&#x000a0;Suggest LMWH use&#x000a0;</td>
                <td style="width: 116.422px; height: 13px;" rowspan="1" colspan="1">Recommend anticoagulation prophylaxis</td>
                <td style="width: 134.906px; height: 13px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum,&#x000a0; especially in breastfeeding women&#x000a0;</td>
              </tr>
              <tr style="height: 26px;">
                <td style="width: 110.5px; height: 26px;" rowspan="1" colspan="1">Yes-past history of DVT treatment (either unprovoked or associated with hormonal risk factors)&#x000a0;</td>
                <td style="width: 114.125px; height: 26px;" rowspan="1" colspan="1">Heterozygous factor V Leiden</td>
                <td style="width: 107.734px; height: 26px;" rowspan="1" colspan="1">Irrespective of family history&#x000a0;</td>
                <td style="width: 175.312px; height: 26px;" rowspan="1" colspan="1">&#x000a0;Suggest LMWH</td>
                <td style="width: 116.422px; height: 26px;" rowspan="1" colspan="1">Suggest anticoagulation prophylaxis&#x000a0;</td>
                <td style="width: 134.906px; height: 26px;" rowspan="1" colspan="1">LMWH during pregnancy and postpartum, especially in breastfeeding women</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>DOACs: Direct oral anticoagulants (examples include rivaroxaban, apixaban, dabigatran, or edoxaban); LMWH: Low molecular weight heparin; DVT: Deep venous thrombosis; PE: Pulmonary embolism&#x000a0;</p>
      </sec>
      <sec id="article-21577.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21577&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21577">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/factor-v-leiden-mutation/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21577">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21577/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21577">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21577.s15">
        <title>References</title>
        <ref id="article-21577.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Dahlb&#x000e4;ck</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V.</article-title>
            <source>Blood</source>
            <year>1999</year>
            <month>Apr</month>
            <day>15</day>
            <volume>93</volume>
            <issue>8</issue>
            <fpage>2552</fpage>
            <page-range>2552-8</page-range>
            <pub-id pub-id-type="pmid">10194434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dzimiri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>World distribution of factor V Leiden.</article-title>
            <source>Lancet</source>
            <year>1996</year>
            <month>Feb</month>
            <day>17</day>
            <volume>347</volume>
            <issue>8999</issue>
            <fpage>481</fpage>
            <page-range>481-2</page-range>
            <pub-id pub-id-type="pmid">8618525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kemkes-Matthes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>P&#x000f6;tzsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kraus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wirbartz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kaps</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Screening for thrombophilic risk factors among 25 German patients with cerebral venous thrombosis.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-6</page-range>
            <pub-id pub-id-type="pmid">10893060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Moerloose</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Reber</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Perrier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perneger</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bounameaux</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of factor V Leiden and prothrombin G20210A mutations in unselected patients with venous thromboembolism.</article-title>
            <source>Br J Haematol</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-9</page-range>
            <pub-id pub-id-type="pmid">10930988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Risk of Budd-Chiari syndrome associated with factor V Leiden and G20210A prothrombin mutation: a meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>e95719</fpage>
            <pub-id pub-id-type="pmid">24755609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Juul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tybjaerg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steffensen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kofoed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses.</article-title>
            <source>Blood</source>
            <year>2002</year>
            <month>Jul</month>
            <day>01</day>
            <volume>100</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-10</page-range>
            <pub-id pub-id-type="pmid">12070000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kourlaba</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Relakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kontodimas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Maniadakis</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of the epidemiology and burden of venous thromboembolism among pregnant women.</article-title>
            <source>Int J Gynaecol Obstet</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>132</volume>
            <issue>1</issue>
            <fpage>4</fpage>
            <page-range>4-10</page-range>
            <pub-id pub-id-type="pmid">26489486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosfors</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nor&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hjertberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Persson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lillthors</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>T&#x000f6;rngren</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A 16-year haemodynamic follow-up of women with pregnancy-related medically treated iliofemoral deep venous thrombosis.</article-title>
            <source>Eur J Vasc Endovasc Surg</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>448</fpage>
            <page-range>448-55</page-range>
            <pub-id pub-id-type="pmid">11735184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wik</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Sandvik</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sandset</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study.</article-title>
            <source>J Thromb Haemost</source>
            <year>2012</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>840</fpage>
            <page-range>840-7</page-range>
            <pub-id pub-id-type="pmid">22452811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carroll</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rebarber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Booker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saltzman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lam-Rachlin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Double versus single thrombophilias during pregnancy.</article-title>
            <source>J Matern Fetal Neonatal Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>19</issue>
            <fpage>2590</fpage>
            <page-range>2590-2593</page-range>
            <pub-id pub-id-type="pmid">28670948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perez Botero</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Majerus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Strege</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.</article-title>
            <source>Am J Clin Pathol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>147</volume>
            <issue>6</issue>
            <fpage>604</fpage>
            <page-range>604-610</page-range>
            <pub-id pub-id-type="pmid">28472350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amiral</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vissac</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Seghatchian</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Laboratory assessment of Activated Protein C Resistance/Factor V-Leiden and performance characteristics of a new quantitative assay.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>906</fpage>
            <page-range>906-913</page-range>
            <pub-id pub-id-type="pmid">29162399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tritschler</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kraaijpoel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Gal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>Venous Thromboembolism: Advances in Diagnosis and Treatment.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Oct</month>
            <day>16</day>
            <volume>320</volume>
            <issue>15</issue>
            <fpage>1583</fpage>
            <page-range>1583-1594</page-range>
            <pub-id pub-id-type="pmid">30326130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalafallah</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Ibraheem</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Albarzan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Parameswaran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pavlov</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dennis</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hannan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Review of Management and Outcomes in Women with Thrombophilia Risk during Pregnancy at a Single Institution.</article-title>
            <source>ISRN Obstet Gynecol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>381826</fpage>
            <pub-id pub-id-type="pmid">24693443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ilonczai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ol&#x000e1;h</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Selmeczi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ker&#x000e9;nyi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bereczky</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>P&#x000f3;ka</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schlammadinger</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Boda</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Management and outcome of pregnancies in women with antithrombin deficiency: a single-center experience and review of literature.</article-title>
            <source>Blood Coagul Fibrinolysis</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>798</fpage>
            <page-range>798-804</page-range>
            <pub-id pub-id-type="pmid">26226254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21577.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rajasekhar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLintock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodger</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Vazquez</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>IA</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>LaHaye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>2</volume>
            <issue>22</issue>
            <fpage>3317</fpage>
            <page-range>3317-3359</page-range>
            <pub-id pub-id-type="pmid">30482767</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
